Hepatitis B Virus News and Research

RSS

Sarcoma Oncology Center, Aethlon Medical to study ex vivo effectiveness of Hemopurifier

Aethlon Medical, Inc., the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that it has entered into an agreement with the Sarcoma Oncology Center to study the ex vivo effectiveness of the Aethlon Hemopurifier to remove immunosuppressive exosomes from the blood of advanced-stage cancer patients.

24 Aug 2011

FDA grants fast track designation for Pharmasset's PSI-938 to treat chronic HCV infection

Pharmasset, Inc. has received fast track designation from the U.S. Food and Drug Administration (FDA) for PSI-938 for the treatment of chronic hepatitis C virus (HCV) infection.

24 Aug 2011

Should we be screening blood for hepatisi G?

Hepatitis G virus was identified in 1995. Some little research was carried out on the virus and the US Food and Drug Administration (FDA) declared it a non-harmful virus in 1997. Researchers in Saudi Arabia, writing in the International Journal of Immunological Studies present evidence to suggest that this may have been the wrong decision.

22 Aug 2011

NIH awards Jefferson $4.8M grant to study vaccine to clear rabies virus from central nervous system

Thomas Jefferson University received a National Institutes of Health (NIH) $4.8 million grant to test a new rabies vaccine with the potential to cure the virus infection, even after it has made its way into a person's central nervous system (CNS). Today, if an unvaccinated person is infected with rabies and it spreads to the brain, there is little chance for survival.

8 Aug 2011

Inhibitex second quarter net loss decreases to $5.3 million

Inhibitex, Inc. today announced its financial results for the second quarter ended June 30, 2011 and provided an update on several recent clinical and corporate developments.

8 Aug 2011

Idera second quarter net loss increases to $6.3 million

Idera Pharmaceuticals, Inc. today reported financial results for the second quarter ended June 30, 2011. Idera is a biotechnology company engaged in the discovery and development of DNA- and RNA-based drug candidates targeted to Toll-Like receptors (TLRs).

5 Aug 2011

Alnylam second quarter revenue decreases to $20.6 million

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today reported its consolidated financial results for the second quarter 2011, and company highlights.

From Precision NanoSystems Inc. 2 Aug 2011

Hepatitis on the rise

According to the World Health Organization (WHO), the battle is on to fight the rising numbers of hepatitis B cases. Medical experts are calling for global action to tackle the viruses that cause the liver disease hepatitis. The first worldwide estimates in drug users show 10 million have hepatitis C while 1.3 million have hepatitis B.

29 Jul 2011

Hepatitis B immunization for health care students may fall short of current recommendations

A study in the August issue of Infection Control and Hospital Epidemiology, the journal of the Society for Healthcare Epidemiology of America (SHEA), suggests that documentation of hepatitis B vaccination for health care students may fall short of current recommendations.

22 Jul 2011

HIV-infected MSM more likely to contract HCV through sex

Sexual transmission of hepatitis C virus (HCV) is considered rare. But a new study by researchers at Mount Sinai School of Medicine, working with the Centers for Disease Control and Prevention (CDC), provides substantial evidence that men with HIV who have sex with other men (MSM) are at increased risk for contracting HCV through sex.

22 Jul 2011

Roche, Merck sign new non-exclusive agreement for HCV triple combination therapy

Merck, known as MSD outside the United States and Canada, announced today that it has signed a new non-exclusive agreement with Roche, through the companies' respective subsidiaries, for the global promotion, upon appropriate marketing approvals, of VICTRELIS (boceprevir) as part of a triple combination therapy regimen with peginterferon alfa and ribavirin.

21 Jul 2011

Final SVR results from Pharmasset's PSI-7977 phase 2b study in HCV

Pharmasset, Inc. announced today the final sustained virologic response (SVR) results from its phase 2b PROTON study with PSI-7977 dosed once daily in combination with peginterferon alfa 2a and ribavirin in subjects with hepatitis C virus (HCV) genotype 2 or 3 who have not been treated previously.

20 Jul 2011

Inovio reports strong immune responses with VGX-3100 vaccine for cervical dysplasia and cancer

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, has reported data demonstrating long-term durability of T cell immune responses of up to over two years (at the latest time measured) in 7 of 8 evaluated patients following a fourth vaccination of VGX-3100, its investigational SynCon® DNA vaccine for treating cervical dysplasia and cancer caused by human papillomavirus (HPV) that is delivered using intramuscular electroporation.

15 Jul 2011

European joint project to develop novel HCV vaccine based on nanotechnology

HCVAX is a European joint project that reaches out to develop a vaccine against hepatitis C based on nanotechnology. The German Helmholtz Centre for Infection Research in Braunschweig and its department "Vaccinology and Applied Microbiology" is now a part of the transnational consortium with researchers from Germany, France and Switzerland.

2 Jul 2011

Gene PNPLA3 offers potential therapeutic target in chronic hepatitis C liver damage

New research confirms that a variant on the patatin-like phospholipase-3 (PNPLA3) gene increases risk of steatosis and fibrosis progression in patients with chronic hepatitis C virus (HCV). The PNPLA3 single nucleotide polymorphism (SNP) rs 738409 may represent an important genetic predictor and potential therapeutic target in chronic HCV liver damage.

29 Jun 2011

Prototype small molecule drugs could suppress hepatitis C

Targeted multi-drug treatments for hepatitis C patients that could stop the virus in its tracks have come a step closer, thanks to researchers at the University of Leeds, UK.

29 Jun 2011

Incivek-combination therapy increases chances of HCV patients achieving viral cure

The drug Incivek, when given in combination with two other medications, can dramatically increase the chances of people chronically infected with untreated genotype 1 hepatitis C virus achieving a viral cure. That's the finding of a study published in the June 23rd issue of the New England Journal of Medicine.

23 Jun 2011

Telaprevir drug shows promise in curing hepatitis C infection

The drug telaprevir (Incivek) provides a dramatic improvement in the treatment of the most common form of hepatitis C infection, says an international team of investigators led by Dr. Ira M. Jacobson of NewYork-Presbyterian Hospital/Weill Cornell Medical Center.